SavedAdd your journal

Journals / Turkish Journal of Pharmaceutical Sciences / 2019 / Cilt: 16 - Sayı: 1

Synthesis and Aldose Reductase Inhibitory Effect of Some New Hydrazinecarbothioamides and 4-Thiazolidinones Bearing an Imidazo[2,1-b] Thiazole Moiety

İmidazo[2,1-b]Tiyazol Çekirdeği Taşıyan Bazı Yeni Hidrazinkarbotiyoamitler ve 4-Tiyazolidinonların Sentezi ve Aldoz Redüktaz İnhibitör Etkileri

Mutlu SARIKAYA
Net DAŞ EVCİMEN
Nuray ULUSOY GÜZELDEMİRCİ
Selin CİMOK
Pages
1–7
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The synthesized compounds were tested for their ability to inhibit rat kidney AR.Results: Among the synthesized compounds, 2-[[6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl]acetyl]-N-benzoylhydrazinecarbothioamide (3d)showed the best AR inhibitory activity.Conclusion: The findings of this study indicate that the different derivatives of the compounds in this study may be considered interesting candidatesfor future research.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: To synthesize and characterize 2-[[6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl]acetyl]-N-alkyl/arylhydrazinecarbothioamide and3-alkyl/aryl-2-[((6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl)acetyl)hydrazono]-5-nonsubstituted/methyl-4-thiazolidinone derivatives andevaluate them for their aldose reductase (AR) inhibitory effect.Materials and Methods: 2-[[6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl]acetyl]-N-alkyl/arylhydrazinecarbothioamides (3a-f) and 3-alkyl/aryl2-[((6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl)acetyl)hydrazono]-5-nonsubstituted/methyl-4-thiazolidinones (4a-j) were synthesized from2-[6-(4-bromophenyl)imidazo[2,1-b]thiazole-3-yl]acetohydrazide (2).
📊
Key Findings & Data:Their structures were elucidated by elemental analyses and spectroscopicdata.
💡
Conclusion & Impact:The synthesized compounds were tested for their ability to inhibit rat kidney AR.Results: Among the synthesized compounds, 2-[[6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl]acetyl]-N-benzoylhydrazinecarbothioamide (3d)showed the best AR inhibitory activity.Conclusion: The findings of this study indicate that the different derivatives of the compounds in this study may be considered interesting candidatesfor future research.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: To synthesize and characterize 2-[[6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl]acetyl]-N-alkyl/arylhydrazinecarbothioamide and3-alkyl/aryl-2-[((6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl)acetyl)hydrazono]-5-nonsubstituted/methyl-4-thiazolidinone derivatives andevaluate them for their aldose reductase (AR) inhibitory effect.Materials and Methods: 2-[[6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl]acetyl]-N-alkyl/arylhydrazinecarbothioamides (3a-f) and 3-alkyl/aryl2-[((6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl)acetyl)hydrazono]-5-nonsubstituted/methyl-4-thiazolidinones (4a-j) were synthesized from2-[6-(4-bromophenyl)imidazo[2,1-b]thiazole-3-yl]acetohydrazide (2). Their structures were elucidated by elemental analyses and spectroscopicdata. The synthesized compounds were tested for their ability to inhibit rat kidney AR.Results: Among the synthesized compounds, 2-[[6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl]acetyl]-N-benzoylhydrazinecarbothioamide (3d)showed the best AR inhibitory activity.Conclusion: The findings of this study indicate that the different derivatives of the compounds in this study may be considered interesting candidatesfor future research.

Özet

Amaç: Bu çalışmanın amacı, 2-[[6-(4-bromofenil)imidazo[2,1-b]tiyazol-3-il]asetil]-N-alkil/arilhidrazinkarbotiyoamit ve 3-alkil/aril-2-[((6-(4- bromofenil)imidazo[2,1-b]tiyazol-3-il)asetil)hidrazono]-5-nonsübstitüe/metil-4-tiyazolidinon türevlerini sentezlemek, yapılarını aydınlatmak ve aldoz redüktaz (AR) inhibitör etkilerini araştırmaktır. Gereç ve Yöntemler: 2-[6-(4-bromofenil)imidazo[2,1-b]tiyazol-3-il]asetohidrazitten (2) hareketle 2-[[6-(4-bromofenil)imidazo[2,1-b]tiyazol-3-il] asetil]-N-alkil/arilhidrazinkarbotiyoamit (3a-f) ve 3-alkil/aril-2-[((6-(4-bromofenil)imidazo[2,1-b]tiyazol-3-il)asetil)hidrazono]-5-nonsübstitüe/ metil-4-tiyazolidinon türevleri (4a-j) sentezlenmiştir. Bileşiklerin yapıları elementel analiz ve spektroskopik bulgularla kanıtlanmıştır. Sentezlenen bileşikler sıçan böbrek AR enzimini inhibe etme özellikleri açısından test edilmiştir. Bulgular: Sentezlenen bileşikler arasından, 2-[[6-(4-bromofenil)imidazo[2,1-b]tiyazol-3-il]asetil]-N-benzoilhidrazinkarbotiyoamit (3d) en iyi AR inhibitör etkiyi göstermiştir. Sonuç: Bu çalışmanın bulguları, bu çalışmadaki bileşiklerin farklı türevlerinin gelecek araştırmalar için ilginç adaylar olarak görülebileceğini göstermektedir.

🔖

Cite This Article

SARIKAYA, M., EVCİMEN, N. D., GÜZELDEMİRCİ, N. U., CİMOK, S. (2022). Synthesis and Aldose Reductase Inhibitory Effect of Some New Hydrazinecarbothioamides and 4-Thiazolidinones Bearing an Imidazo[2,1-b] Thiazole Moiety. Turkish Journal of Pharmaceutical Sciences, Cilt: 16 - Sayı: 1, 1–7. https://ajindex.com/articles/613807

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. World Health Organization (WHO). WHO, Global report on diabetes, 2016
  2. Forbes JM, Cooper ME. Mechanism of diabetic complications. Physiol Rev. 2013;93:137-188
  3. Brownlee, M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615-1625
  4. El-Kabbani O, Ruiz F, Darmanin C, Chung RP. Aldose reductase structures: implications for mechanism and inhibition. Cell Mol Life Sci. 2004;61:750-762
  5. Hers HG. The mécanism of the transformation de glucose in fructose in the seminal vesicles. Biochim Biophys Acta. 1956;22:202-203
  6. Srivastava SK, Ramana KV, Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev. 2005;26:380-392
  7. Alexiou P, Pegklidou K, Chatzopoulou M, Nicolaou I, Demopoulos VJ. Aldose reductase enzyme and its implication to major health problems of the 21(st) century. Curr Med Chem. 2009;16:734-752
  8. Frank RN. Diabetic retinopathy. N Engl J Med. 2004;350:48-58
  9. Sheetz MJ, King GL. Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. JAMA. 2002;288:2579-2588
  10. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820
  11. Yabe-Nishimura C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol Rev. 1998;50:21-33
  12. Obrosova IG, Minchenko AG, Vasupuram R, White L, Abatan OI, Kumagai AK, Frank RN, Stevens MJ. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes. 2003;52:864- 871
  13. Yan SF, Ramasamy R, Naka Y, Schmidt AM. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res. 2003;93:1159-1169
  14. Del-Corso A, Balestri F, Di Bugno E, Moschini R, Cappiello M, Sartini S, La-Motta C, Da-Settimo F, Mura U. A New Approach to Control the Enigmatic Activity of Aldose Reductase. PLoS One. 2013;8:74076
  15. Kumar PA, Reddy GB. Focus on molecules: aldose reductase. Exp Eye Res. 2007;85:739-740
  16. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994;331:1188-1193
  17. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabet